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Background: Vitamin D is essential in the host defence against tuberculosis (TB) as an immune modu-
lator. The aim of this study was to determine the level of 25-hydroxyvitamin D (25 (OH) D) from adult TB
index cases before and after treatment and their exposed household contacts (HHC) in The Gambia.
Methods: Serum from adult index TB cases and their TB-exposed household contacts (HHC) was analysed
for 25(OH) D and Vitamin D binding protein (VDBP) concentrations. Tuberculin skin test (TST) status was
used as a measure ofMycobacterium tuberculosis (Mtb) infectivity in the HHC. In addition, HHC who later
progressed to active TB (incident cases) were assessed alongside non-progressors to determine the
inﬂuence of 25 (OH) D levels on TB risk.
Results: Eighty-three TB cases, 46 TSTþ and 52 TST HHC were analysed. Generally levels of 25(OH) D
were considered insufﬁcient in all subjects. However, median levels of 25(OH) D and VDBP were
signiﬁcantly higher in TB cases compared to both TSTþ and TST HHC at recruitment and were signif-
icantly reduced after TB therapy (p < 0.0001 for all). In addition, levels of serum 25(OH) D at recruitment
were signiﬁcantly higher in TB progressors compared to non-progressors (median (IQR): 25.0(20.8e29.2)
in progressors and 20.3 (16.3e24.6) ng/ml in non-progressors; p ¼ 0.007).
Conclusion: In The Gambia, an equatorial country, 25(OH) D levels are higher in serum of TB progressors
and those with active disease compared to latently infected and uninfected subjects. These results
contrast to ﬁndings in non-equatorial countries.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The global burden of Tuberculosis (TB) is huge, with an esti-
mated one-third of the world population latently infected [1,2], 9
million new cases and 1.5 million deaths per year [3]. In a life-time,
10% of infected individuals progress to active TB disease in immune
competent individuals increasing to 10% per year in HIV co-infected
individuals [4]. One of the major contributing factors to disease
progression in HIV uninfected individuals is malnutrition [5] with
micronutrient deﬁciencies such as vitamins A, B6, E, thiamine,
folate, and zinc reported in patients with active TB disease [6]. 25-
hydroxyvitamin D (25(OH) D) has been implicated in the hostBanjul, Gambia. Tel.: þ220
r Ltd. This is an open access articledefence against TB as an immune modulator [1,7,8]. Indeed, treat-
ment of TB decades ago included exposure to the sun for enhanced
25(OH) D synthesis, but the mechanismwas not clear [9]. 25(OH) D
has been shown to down-regulate the pro-inﬂammatory response
and therefore may help to protect the host against increased lung
pathology induced by exacerbated inﬂammation [10]. It also has
anti-microbial effects by inducing activation of macrophages [11]. A
seminal paper in Science demonstrated the link between 25(OH) D
and IFN-g induced macrophage antimicrobial responses [12].
The majority of studies analysing the role of 25(OH) D in TB have
shown an association between low 25(OH) D and susceptibility to
active TB disease [13e16]. However, there are still discrepancies in
terms of genetic predisposition [17,18] and serum levels in TB and
non-TB subjects [19,20]. This is likely due to geographic location,
exposure to sunlight, genetic differences, cultural practices, religion
and the presence of other disease conditions [21]. A recent study in
Greenland, for example, showed large variation of Serum 25(OH) Dunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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crease the risk of TB amongst those with normal or high concen-
trations [22]. Indeed, clinical trials in Guinea-Bissau and Georgia
and a meta-analysis of all trials that used 25(OH) D supplementa-
tion as adjunctive therapy have shown no clinical beneﬁts [23e25].
In HIV-infected patients in Uganda, no difference in 25(OH) D levels
was seen in subjects with and without TB [23], while a Malawi
study among TB patients with over 50% HIV co-infection rates
showed that deﬁciency in the levels of 25(OH) D was common and
had no inﬂuence on response to treatment [27].
The genetic predisposition to TB associated with Vitamin D re-
ceptor (VDR) gene polymorphisms was considered a prime candi-
date for TB susceptibility but results from a meta-analysis have
proved inconclusive [17] although a link between VDR poly-
morphisms and response to therapy in terms of time to fast sputum
conversion ratewith anti TB treatment in FF; Taql Tt and non-FF; TT
genotypes respectively for pulmonary TB has been suggested [24].
These discrepancies are further highlighted by a recent study
showing no beneﬁt of 25(OH) D supplementation on response to
therapy in an Indian population [25] although it may limit lung
pathology and thus reduce disability-associated life-years (DALYs)
in vulnerable populations [26].
InWestAfrica, there appears tobea role forVDRhaplotypes rather
than genotypes in susceptibility toTB [18], although another study in
Guinea Bissau showed VDR polymorphisms when analysed together
with ethnicity were associated with increased risk of TB disease [27].
Interestingly, there also appears to be an inﬂuence of variationwithin
the gene encoding Vitamin D binding protein (VDBP) and Serum
25(OH) D levels in Gambian children [28], which has implications for
interpretation of 25(OH) D status across different groups. However,
no study has been performed in The Gambia to determine the serum
levels of 25(OH) D in TB patients, TSTþ and TST contacts.
Due to our powerful TB case-contact platform in The Gambia
[29], we are able to analyse individuals across the spectrum of TB
infection and disease. Thus, the aim of this study was to compare
the level of Serum 25(OH) D and VDBP in adult TB cases before and
after treatment and their exposed household contacts (both TSTþ
and TST). Importantly, we also analysed exposed subjects who
progressed to active TB disease between 3 and 24 months from
recruitment. This is the ﬁrst study in Gambia, an equatorial country,
to determine 25(OH) D levels and association with TB. In complete
contrast to the majority of studies in non-equatorial countries, we
found higher 25(OH) D levels in TB cases compared to TSTþ and
TST HHC. Importantly, levels decreased with treatment and were
higher in subjects who progressed to active TB, indicating that in
our setting higher 25(OH) D is associated with TB risk.
2. Materials and methods
2.1. Study participants and design
Adult TB cases were recruited from the Medical Research
Council (MRC) TB clinic in Fajara, The Gambia. The diagnosis of
active TB was established on the basis of smear positivity for acid-
fast bacilli of Mycobacterium tuberculosis (Mtb). All mycobacterial
cultures were identiﬁed and conﬁrmed using standard procedures.
Household contacts (HHC) of conﬁrmed index cases were visited to
assess their TB infection status and were followed for 2 years from
recruitment. Tuberculin skin test (TST) was used as a measure of
mycobacterial infection and was performed using 2 tuberculin
units of puriﬁed peptide derivative RT23 (SSI, Denmark) injected
intra dermally into the volar aspect of the forearm and read at
48e72 h. TST was performed prior to any blood sampling of study
participants. A reading of 10 mm was considered positive, and
indicative of mycobacterial infection. The diagnosis of latent TBinfection was established on the basis of absence of TB symptoms,
absence of radiologic abnormalities of active TB (all contacts had
chest X-ray performed) and positivity for TST.
25(OH) D was measured at recruitment and 6 months after
recruitment for adult TB cases but measured only at recruitment for
TSTþ and TST HHC. The VDBP was measured for a random sub-
sample of TB cases, TSTþ and TST HHC (n ¼ 24 cases at 0 and 6
months; 27 TSTþ HHC and 28 TST HHC). These had similar age
and sex distributions to the larger cohort (not shown). A matched
caseecontrol study was also conducted to analyse TB progressors
(deﬁned as asymptomatic at recruitment but progressing to active
disease between 3 and 24 months [29] and matched (by age and
sex)) to non-progressors in a 1:3 ratio. Serum samples from all
subjects were collected and stored at 20 C until analysis. All
participants in this study gave written informed consent.
2.2. Measurement of 25(OH) D levels
Serum 25(OH) D concentrations were determined using a
Vitamin D total ELISA (DIAsource Immunoassays, Belgium) ac-
cording to the manufacturer's instructions. A 4-parameter logistic
function curve was used to determine the 25(OH) D concentrations
of the samples from the calibration curve. 25(OH) D levels were
deﬁned as: Deﬁciency: 0e10 ng/ml; Insufﬁciency: 10e30 ng/ml;
Sufﬁciency: 30e150 ng/ml and toxicity: >150 ng/ml.
2.3. Measurement of vitamin D binding protein levels
In order to determine the free, bioactive levels of 25(OH) D, we
analysed Serum Vitamin D binding protein (VDBP) using an ELISA-
based method (Immundiagnostik, Germany) according to manu-
facturer's instructions. A 4-parameter standard curve was con-
structed and levels of VDBP determined in each sample. Results
were multiplied by 40,000 and converted to mg/dl.
2.4. Statistical analysis
The 25(OH) D level at recruitment was compared between TB
groups using Wald adjusted test accounting for clustering within
households. Unadjusted and adjusted mixed effects models were
performed with age, gender and season at recruitment as potential
confounders. We investigated the relationship between 25(OH) D
and BMI using amultilevel structural equationmodelling accounting
for clustering within households. Wilcoxon signed rank test and
Wald adjusted test were used to compare the 25(OH) D and VDBP
levels between TB groups at 0 and 6 months. Pearson chi-squared
test with second-order correction of Rao and Scott accounting for
clustering within households was used to assess association be-
tween TB groups and categorical variables such as gender and
25(OH) D category (i.e. insufﬁcient versus sufﬁcient) at recruitment.
Wald test with adjustment for confounders using linear regression
was used to analyse progressors and non-progressors.
3. Results
3.1. Participant demographics
We analysed a total of 181 HIV sero-negative participants con-
sisting of 83 conﬁrmed TB cases, 46 TSTþ HHC and 52 TST HHC
(Table 1). A total of 12 incident cases (progressing to active TB be-
tween 3 and 24 months from recruitment) were detected and
matched by age and sexwith 32 HHCwho did not progress to active
TB. There was no difference in age between TB cases, TSTþHHC and
TST HHC but a signiﬁcant difference in the proportion of males in
the TB index case group (71.1%), TSTþ (52.2%) and TST (36.5%)
Table 1












Age, median (IQR)) 28 (23e39) 24 (22e33) 23 (20e35) 0.08* 30.5 (21e56) 26 (20e49) 0.39z
Male, n (%) 59 (71.1) 24 (52.2) 19 (36.5) 0.002y 8 (66.7) 23 (71.9) 0.74x
BMI at recruitment,
median (IQR)
17.6 (16.3e19.4) 20.6 (19.1e22.7) 20.3 (18.7e23.6) <0.0001* 20.7 (17.7e21.4) 21.4 (19.7e24.7) 0.07z
Vitamin D level,
median (IQR)





22 (26.5) 2 (4.3) 0 (0.0) 3 (25.0) 1 (3.1)
Insufﬁciency (10e30 ng/ml),
n (%)
59 (71.1) 42 (91.3) 49 (94.2) 9 (75.0) 31 (96.9)
Deﬁciency (0e10 ng/ml),
n (%)
2 (2.4) 2 (4.3) 3 (5.8) 0 (0.0) 0 (0.0)
Age and sex were used to match TB incident cases to non-progressors.
* Wald adjusted test accounting for clustering within households.
y Pearson chi-squared test with second-order correction of Rao and Scott accounting for clustering within households.
z Wald test from mixed effects linear regression accounting for matched-pairs clustering.
x Wald test from mixed effects logistic regression accounting for matched-pairs
clustering.
Figure 1. 25(OH) D levels in TB cases and household contacts (HHC). A: Serum 25(OH)
D levels were measured using ELISA. Box plots (5e95%) are shown for Serum 25(OH) D
levels of TB cases at recruitment (R) and 6 months of treatment and TSTþ and TST
HHC at recruitment. Line indicates median and dots indicate outliers. B: Serum
Vitamin D Binding Protein levels were measured using ELISA. Box plots (5e95%) are
shown for TB cases pre and post-treatment compared to TSTþ and TST HHC. Data
were analysed using Random effects modelling and Wilcoxon Ranked Sums test (for
comparison of TB cases at recruitment and 6 months). A p-value  0.05 was considered
signiﬁcant.HHC groups (p ¼ 0.002). As expected, BMI was signiﬁcantly lower
in TB cases compared to both TSTþand TSTHHC (median (IQR) for
TB cases was 17.6 (16.3e19.4) compared to 20.6 (19.1e22.7) and
20.3 (18.7e23.6) kg/m2 for TSTþ and TST HHC respectively)
(Table 1). Due to differences in age and sex and possible household
clustering, all results have been adjusted for these variables.
3.2. Serum 25(OH) vitamin D levels
26.5% of TB cases had sufﬁcient levels (30e150 ng/ml) of 25(OH)
D compared to 4.3% of TSTþ HHC and 0% TST HHC (p ¼ 0.0001),
while 2.4% of TB cases, 4.3% TSTþ HHC and 5.8% of TST HHC had
deﬁcient levels according to the Endocrinology Society [30]. The
median (interquartile range (IQR)) 25(OH) D levels were signiﬁ-
cantly higher in TB cases pre-treatment compared to both the TSTþ
and TST HHC (23.6 (17.1e30.3), 17.4 (14.9e21.1) and 16.3
(13e19.6) ng/ml respectively; p < 0.0001 for both; Figure 1a).
Following successful TB treatment, 25(OH) D levels signiﬁcantly
decreased from pre-treatment to post-treatment levels (median
(IQR): 23.6 (17.1e30.3), 21.3 (16.6e27.3); p ¼ 0.02; Figure 1a)
respectively, but were still signiﬁcantly higher than the HHC
(p ¼ 0.007 for TSTþ and p < 0.0001 for TST). We used a multi-
variable linear regression model to adjust for age, gender, house-
hold clustering and season at recruitment. None of these variables
had any confounding effects on the relationship between TB groups
and 25(OH) D at recruitment (Table 2). Levels remained relatively
constant throughout the year with a slight but not signiﬁcant dip in
March (Figure 2). However, this was adjusted for and had no con-
founding effects on the relationship between TB groups.
We did not include BMI as potential confounder because BMI
falls into the causal pathway for TB. However, we investigated
whether BMI acted as a mediator between TB groups and 25(OH) D
levels using a multilevel structural equation modelling. There was
no evidence of mediation effect of BMI on the relationship between
TB group and 25(OH) D level, adjusted for age, gender and season at
recruitment (data not shown).
3.3. Analysis of vitamin D binding protein levels
In order to determine if there were differences in the functional
component of 25(OH) D, we analysed Vitamin D binding protein
(VDBP), measured on a random sub-sample of TB cases (n ¼ 24),
TSTþ HHC (n ¼ 27) and TST HHC (n ¼ 28). These subjects had
similar age and sex distribution compared to the larger cohort (not
Table 2
Estimated effects of TB group, age, gender and season at recruitment on Vitamin D level at recruitment.
Variables Unadjusted effect (95% CI)* p Adjusted effect (95% CI)* p
TB group <0.0001y <0.0001y
Active TB 0 0
TSTþ HHC 7.20 (10.9, 3.52) <0.0001 7.02 (10.7, 3.33) 0.001
TST HHC 9.72 (13.0, 6.46) <0.0001 9.14 (12.6, 5.7) <0.0001
Age 0.004 (0.12, 0.11) 0.95 0.07 (0.17, 0.04) 0.20
Gender
Female 0 0
Male 4.87 (1.66, 8.07) 0.003 2.38 (0.55, 5.32) 0.11
Season at recruitment
Dry 0 0
Wet 1.92 (6.40, 2.55) 0.40 0.53 (4.42, 3.37) 0.79
* 95% Conﬁdence intervals.
y Joint Wald test assessing overall evidence association between TB group and vitamin D level. Other p-values are also derived fromWald test assessing the signiﬁcance of
the estimated effects. For continuous and binary variables, Wald tests assess both signiﬁcance of estimates and overall evidence of association with vitamin D level.
Figure 2. Median 25(OH) D levels of TB cases and Household contacts (HHC) at
recruitment. Median 25(OH) D levels at each month of recruitment for all participants
are shown to reﬂect changes in levels of 25(OH) D levels.
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respect toTB status: TB cases had signiﬁcantly higher levels of VDBP
compared to both TSTþ and TST HHC (median (IQR) ¼ 52.6
(49.2e61.7), 43.4 (39.5e48.7) and 42.8 (39.1e45.3) mg/dl respec-
tively; p ¼ 0.01 compared to TSTþ and p < 0.0001 compared to
TST HHC; Figure 1b). Additionally, levels were signiﬁcantly
reduced in TB cases following treatment (median (IQR): 38.0
(33.0e42.3) mg/dl; p < 0.0001 compared to pre-treatment levels)
and were comparable to TST HHC (p ¼ 0.25) but signiﬁcantly
lower than TSTþ HHC (p ¼ 0.02; Figure 1b).3.4. Increased 25(OH) D levels in incident TB cases
The median (IQR) 25(OH) D level at recruitment was signiﬁ-
cantly higher at recruitment for the incident cases (progressors)
(25.0 (20.8e29.2) ng/ml) compared to the non-progressors (20.3
(16.3e24.6) ng/ml; p ¼ 0.0006; Table 1). The 25(OH) D was higher
in progressors than non-progressors (95% CI: 1.20, 7.53; p ¼ 0.007)
after adjusting for season at recruitment (Table 3).4. Discussion
25(OH) D has been implicated in the immune response to Mtb
infection by inﬂuencing the inﬂammatory response andsubsequent anti-microbial immunity [12]. This has led to the hy-
pothesis that 25(OH) D is important in the control of Mtb infection
and therefore individuals with insufﬁcient levels are more sus-
ceptible to disease. However, in our study, we found the converse:
patients with active TB had insufﬁcient but signiﬁcantly higher
levels of 25(OH) D and VDBP compared to asymptomatic controls
and this level was reduced by 6 months of anti-TB therapy.
Furthermore, household contacts that progressed to active disease
within 3e24 months had higher levels of 25(OH) D at recruitment
thanmatched controls that did not progress. These ﬁndings suggest
that higher levels of 25(OH) D than in the general population might
be a risk factor for TB disease progression in Gambian adults.
Currently, there is little data available on 25(OH) D and suscep-
tibility to infections in West Africa. In addition, while poly-
morphisms in the VDR have been seen in Gambians (for example the
genotype tt (suggesting resistance to clinical TB) were underrepre-
sented in adult TB cases samples compared with controls), these
could not be deﬁnitively linked to TB susceptibility [31]. Interest-
ingly, the majority of studies demonstrating insufﬁcient 25(OH) D in
TB patients have been performed in countries with distinct summer
andwinter seasons and thus differences in levels of natural sunlight.
The only other study we found that showed similar results to ours
was in Uganda, suggesting that there could be geographical differ-
ences in the immunological effects of 25(OH) D. Importantly, our
results show no confounding with season, gender or age.
We did not assess the downstream production of the active form
of 1, 25-dihydroxy D (1, 25(OH) 2 Ds). However, analysis of 25(OH)
D is preferable to assess nutritional Vitamin D status and to di-
agnose 25(OH) D deﬁciency and insufﬁciency while 1,25(OH)2 D is
more applicable for correlation with VDR polymorphisms [32]. The
increase in 25(OH) D levels in asymptomatic subjects who later
progressed to active TB might suggests that elevated 25(OH) D is a
risk factor for TB disease progression in our setting and that sup-
plementation may be detrimental.
The limitations of our study were a lack of mechanistic insight,
insufﬁcient powering and absence of longitudinal measurements in
the contacts. Themechanisms of action of 25(OH) D are complex and
diverse [33] and should be analysed in conjunction with VDR
polymorphisms. Future work should include mechanistic ap-
proaches such as in vitro manipulation with Vitamin D compounds
to assess anti-microbial immunity in blood from Gambian TB pa-
tients. In addition, our ﬁndings by ELISA should be conﬁrmed by
mass spectrometry, which is superior formeasuring 25(OH) D levels.
It is plausible that the differences we see in 25(OH) D levels in
active TB disease in Gambians is a contributing factor to the un-
derlying immune differences between West Africans and other
geographically-diverse subject: for example IFN-g production
Table 3
Unadjusted and adjusted association between vitamin D level and TB progressors, adjusted for season at recruitment.
Variables Unadjusted effect (95% CI)* py Adjusted effect (95% CI) py
Incident cases
Non-progressor 0 0
Progressor 4.21 (1.31, 7.13) 0.005 3.65 (0.59, 6.71) 0.02
Season at recruitment
Dry 0
Wet 1.72 (1.47, 4.92) 0.29
* 95% Conﬁdence intervals.
y Wald test.
O. Owolabi et al. / Tuberculosis 98 (2016) 86e9190followingMtb antigen stimulation in studies involving ﬁve different
sub-Saharan African countries [34]. We did not analyse 25(OH) D in
relation to disease severity, particularly cavitary disease by chest x-
ray, but it would be of interest to see if Gambian subjects have
reduced levels of TB lung-sequelae compared to patients from other
countries with reduced 25(OH) D. A larger cohort powered to assess
lung function before and after therapy would be beneﬁcial.
In conclusion, insufﬁcient 25(OH) levels are not a risk factor for
TB disease in HIV uninfected Gambian adults. Conversely, elevated
25(OH) D appears to be a risk factor for progression to active dis-
ease. Our ﬁndings suggest that Vitamin D supplementation is un-
likely to be beneﬁcial.
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